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Abstract: Porcine cytomegalovirus (PCMV) infection is widely prevalent among pigs, and PCMV is
one of the viruses which may be transmitted during xenotransplantation using pig cells, tissues, or
organs. While human cytomegalovirus (HCMV) is a major risk factor for allotransplantation, it is
still unclear whether PCMV is able to infect human cells or pose a risk for xenotransplantation.
Previously, it was shown that transmission of PCMV after pig kidney to non-human primate
transplantations resulted in a significantly reduced survival time of the transplanted organ. To
detect PCMV, PCR-based and immunological methods were used. Screening of pigs by Western blot
analyses using recombinant viral proteins revealed up to 100% of the tested animals to be infected.
When the same method was applied to screen human sera for PCMV-reactive antibodies, positive
Western blot results were obtained in butchers and workers in the meat industry as well as in normal
blood donors. To exclude an infection of humans with PCMV, the sera were further investigated.
PCMV is closely related to human herpesvirus-6 (HHV-6) and human herpesvirus-7 (HHV-7), and
a sequence alignment of glycoprotein B suggests that the antibodies may cross-react with identical
epitope sequences. HCMV is not related with PCMV, and no correlation between antibody reactivity
against PCMV and HCMV was detected. These data indicate that antibodies against PCMV found in
humans are cross-reactive antibodies against HHV-6.
Keywords: porcine cytomegalovirus; human cytomegalovirus; xenotransplantation; virus
transmission; human herpesvirus-6
1. Introduction
Herpesviruses are double-stranded DNA viruses with a diameter of 150–200 nm, causing diseases
in animals as well as in humans. In humans, nine herpesviruses were found, herpes simplex viruses
1 and 2 (HSV-1 and HSV-2, also known as HHV-1 and HHV-2), varicella-zoster virus (VZV, HHV-3),
Epstein-Barr virus (EBV or HHV-4), human cytomegalovirus (HCMV or HHV-5), two variants of
the human herpesvirus 6 (HHV-6A and HHV-6B), human herpesvirus 7 (HHV-7), and Kaposi's
sarcoma-associated herpesvirus (KSHV, also known as HHV-8) [1]. Herpesviruses were also found in
many other species, including pigs [2]. Suid herpesvirus-1 (SuHV-1) corresponds to the pseudorabies
virus, SuHV-2 to the porcine cytomegalovirus (PCMV), and SuHV-2, -3, and -4 to the porcine
lymphotropic herpesviruses (PLHV)-1, -2, and -3. SuH1 belongs to the subfamily alphaherpesvirinae,
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and PLHVs belong to the subfamily gammaherpesvirinae, genus Macavirus [2]. PCMV was recently
defined as a betaherpesvirus, genus Roseolovirus [3]. This implies that PCMV is more closely related to
the human roseoloviruses HHV-6 and HHV-7 compared with the namesake human cytomegalovirus
(HCMV, or HHV-5) [3].
In the context of virus safety of xenotransplantation using pig cells, tissues, or organs as
replacement for human transplants, PCMV may be transmitted to the recipient (for review see [4]).
Xenotransplantation is under development due to the increasing shortage of human transplants, and
this new technology has made significant progress in the last years [5,6]. Whether PCMV represents
a risk factor for human xenotransplant recipients is still unclear. HCMV, a betaherpesvirus, genus
Cytomegalovirus, is well known as a major risk factor for human allotransplantation and an important
cause of morbidity and mortality in immunocompromised individuals [7].
It still remains controversial whether PCMV is able to infect and replicate in human cells, as
has been demonstrated for other non-human cytomegaloviruses, such as mouse CMV [8]. In one
report, PCMV was shown to infect primary human fibroblasts, to induce cytopathogenic effects in
human cells, and to transcribe PCMV genes resulting in the synthesis of PCMV proteins [9], whereas
in another report, human kidney 293 and Raji B cell lines did not support PCMV replication [10].
Evidence for a putative risk posed by PCMV in xenotransplantation was obtained when kidneys
from PCMV-infected and uninfected pigs were transplanted into cynomolgus monkeys and baboons.
In both cases the survival time of the transplant from the infected pigs was drastically reduced
compared with the transplant from uninfected pig donors [11,12]. Although there was no evidence
of a direct infection of non-human primate cells with PCMV, the dysfunction and transplant failure
were interpreted to result from PCMV infection or replication [11,12]. Transmission of PCMV was also
observed after pig heart transplantation, which was associated with injury of the transplant and an
increased incidence of consumptive coagulopathy [13]. Early weaning excluded PCMV, resulted in a
prolonged survival of the transplant and prevented consumptive coagulopathy [13].
To evaluate the possibility that PCMV may occasionally infect humans, human sera, mainly
from individuals having close contact with pigs, were analyzed for PCMV-reactive antibodies as an
indirect evidence of infection. To study the antibody response a newly developed Western blot assay
comprising four recombinant protein sequences, two corresponding to the N-terminal and C-terminal
part of the glycoproteinB (gB) of PCMV [14] and two newly produced tegument proteins, were applied
as antigens. In addition, an analysis of the sequences of PCMV and other herpesviruses was performed.
2. Materials and Methods
2.1. Recombinant Antigens and Western Blot Analysis for the Detection of PCMV-Specific Antibodies
Two recombinant proteins corresponding to the N-terminus (nucleotides, nt, 539–929) and
C-terminus (nt 2771–3118, Acc. No: AF268039) of the sequence of the glycoprotein gB of PCMV were
used as antigens [14]. These domains are highly conserved among the 46 sequences of PCMV analyzed.
Both sequences were expressed as 10× His-tagged recombinant fusion proteins in E. coli BL21cells
(New England Biolabs, Frankfurt am Main, Germany) and purified by affinity chromatography using
HisTrap columns (GE Healthcare, Buckinghamshire, UK). The tegument proteins U54A and U54B
of PCMV [3] were expressed and purified as follows: The U54A sequence is located at position
70307–72304 (protein ID: AGT99246.1, GenBank No. KF017583) and the sequence of U54B is located
at position 72345–73541 (protein ID: AGT99247.1, GenBank No. KF017583). The sequences were
codon-optimized by the JAVA codon adaptation tool (JCAT) algorithm for E. coli expression [15] and
synthesized by ATGbiosynthetics (Merzhausen, Germany). The synthetic gene sequences were cloned
into the expression vector pet16b (Novagen, Madison, WI, USA) using the restriction enzymes NdeI
and XhoI (New England Biolabs). The cloned sequences were confirmed by Sanger sequencing. Both
sequences were expressed as recombinant His-tagged fusion proteins in E. coli BL21cells (New England
Biolabs). The transformed E. coli cultures were diluted from an overnight culture to an optical density
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at 600 nm wavelength (OD600) of 0.1 in 2 L 2YT-Medium (1.0% yeast extraxt, 1.6% tryptone, pH 7.0).
The E. coli cultures were then grown at 37 ◦C until they reached an OD600 of 0.7, followed by induction
with 1 M isopropyl β-D-1-thiogalactopyranoside (IPTG). After 3 h of induction, cells were pelleted at
8000 rpm for 15 min and stored at −20 ◦C until purification. E. coli cell pellets were resuspended in
buffer phosphate-buffered saline (PBS), 1 mg/mL lysozyme, Sigma-Aldrich, St. Louis, MO, USA, and
50 µL DNase, Thermo Fisher, Waltham, MA, USA), sonicated three times for 20 s, and incubated on
ice for 20 min. The cell debris was removed by centrifugation (10,000 rpm, 10 min) and pellets were
extracted with lysis buffer (6 M guanidinium chloride, 500 mM NaCl, 20 mM disodium phosphate,
pH 7.5) for 1 h under shaking at room temperature. Solubilized proteins were separated from the
remaining insoluble material by centrifugation (25,000 rpm, 20 min), diluted to 100 mL with lysis buffer,
and loaded on HisTrap 5 mL excel columns (GE Healthcare, Buckinghamshire, UK). The columns were
equilibrated with lysis buffer and loaded with solubilized proteins. After washing with lysis buffer
and a second wash buffer (8 M urea, 500 mM NaCl, 15 mM imidazole, 20 mM disodium phosphate,
pH 7.5) the proteins were eluted using a 10-column volume gradient with elution buffer (8 M urea,
500 mM NaCl, 500 mM imidazole, 20 mM disodium phosphate, pH 7.5).
The Western blot analysis was performed as described previously [14,16], using 500 ng/lane
His-tagged gB protein. The proteins were dissolved in sample buffer (50 mM Tris-HCl, 12% glycerol,
4% sodium dodecyl sulfate (SDS), 5% β-mercaptoethanol, 0.01% bromophenol blue) and denaturated
for 5 min at 95 ◦C prior to electrophoresis, and then analyzed using 10% or 14% polyacrylamide gel and
as a molecular weight marker of the PageRuler pre-stained protein ladder (Thermo Fisher). Proteins
were transferred for 50 min to nitrocellulose membranes by electroblotting (15 V) and stained with
Ponceau red, cut into strips, and blocked over night at 4 ◦C with 5% blotting grade dry milk (Carl Roth,
Karlsruhe, Germany) in PBS with 0.05% Tween 20 (blocking buffer). Strips were incubated with sera
diluted 1:300 in blocking buffer for 2 h at room temperature. Polyclonal goat anti-pig immunoglobulin
G (IgG)-alkaline phosphatase (AP) (Abcam, Cambridge, UK) was diluted 1:1000 in blocking buffer.
For the detection of the gB and tegument proteins, a 1:1000 dilution of the Penta-His antibody (Qiagen,
Hilden, Germany) as the primary antibody and 1:1000 polyclonal rabbit anti-mouse IgG-horseradish
peroxidase (HRP) or IgG-AP (Dako, Hamburg, Germany) were used as well. Staining was performed
with 3,3′-diaminobenzidine (DAB) (Thermo Fisher) or with 5-bromo-4-chloro-3-indolyl-phosphate
nitro blue tetrazolium (NBT/BCIP) (Promega, Madison, WI, USA). All Western blot analyses were
repeated two to five times.
2.2. Sera
Sera from 11 Göttingen minipigs, which are the result of cross-breeding the Minnesota minipig,
the Vietnamese potbelly pig, and the German Landrace pig (Ellegaard Göttingen Minipigs A/S,
Dalmose, Denmark, http://www.minipigs.dk/), from 12 Aachen minipigs, which are based on
cross-breeding minipigs derived from different private minipig farms located mainly in Eastern
Germany [17] and 12 animals for slaughter from an abattoir near Berlin, Germany (slaughterhouse
pigs), were collected and stored at −80 ◦C. Sera from butchers and individuals working in the meat
production industry as well as sera from healthy blood donors tested previously for antibodies against
porcine endogenous retroviruses (PERV) [18] were used. Cytotect (Biotest, Dreiech, Germany) was
used, which is a licensed anti-HCMV polyclonal immunoglobulin preparation from human plasma
from HCMV-positive individuals. In addition, 10 human sera samples were analyzed, which had been
shown to be positive or negative for HCMV antibodies using the LIAISON CMV IgG II assay (DiaSorin,
Saluggia, Italy). Finally, two human sera samples negative for HHV-6 and four human sera samples
positive for HHV-6 antibodies, as shown by an immunofluorescence assay, were analyzed. The use
of human blood was approved by the ethics commission at the Medical Faculty of the Humboldt
University Berlin. Written informed consent was provided by study participants.
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2.3. Nucleotide Sequence Alignment
In order to confirm the immunological cross-reactivity between PCMV (accession number
AF268039), HHV-6A (AAA43846), HHV-6B (ARM61233), and HHV-7 (YP073779) at the sequence
level, an alignment of the sequences of the glycoproteins of human herpes viruses and PCMV was
performed using the software DNASTAR Lasergene 10, Clustal W method [19].
2.4. Assay for the Detection of Antibodies against HCMV
Screening for HCMV-specific antibodies was performed at the Laboratory “Labor Berlin”
of the Charite and the Vivantes hospitals, Berlin, using the Abbott Architect CMV IgG
chemiluminescent microparticle immunoassay (CMIA). At the University of Freiburg, Faculty of
Medicine, HCMV-reactive antibodies were estimated using the LIAISON CMV IgG II assay (DiaSorin).
2.5. Immunofluorescence Assays for the Detection of Antibodies against HHV-6 and HHV-7
Antibodies against HHV-6 were screened for binding by an indirect immunofluorescence assay
using HHV-6 strain U1102-infected and uninfected HSB-2 cells, as previously described [20]. Briefly,
infected cells were harvested 4 to 5 days after infection, washed in PBS, air-dried on slides, and fixed for
10 min in ice-cold acetone. Fixed cells were incubated with either human or porcine sera at dilutions of
1:16 and 1:64 in PBS for 30 min at 37 ◦C. After removal of the diluted sera, the slides were washed twice
for 5 min in PBS at room temperature with gentle agitation. This was followed by incubation with
fluorescein isothiocyanate (FITC)-conjugated goat anti-human or anti-pig IgG for 30 min at 37 ◦C. After
washing in PBS as above, the cells were briefly counterstained with a 1:20,000 dilution of Evans Blue
and mounted with 50% glycerol in PBS. Slides were examined using a Zeiss fluorescence microscope
(Carl Zeiss, Oberkochen, Germany) at 250× magnification. All assays were repeated at least two times.
2.6. Real-Time PCR for the Detection of PCMV
A duplex real-time PCR was performed as described previously [14], using primers
specific for PCMV (forward (fw) ACTTCGTCGCAGCTCATCTGA, 45206–45226, KF017583.1,
reverse (rev) GTTCTGGGATTCCGAGGTTG, 45268–45249 and probe 6FAM-CAGGGCGGCG
GTCGAGCTC-TAMRA, 45246–45229) [21] and porcine glycerinaldehyd-3-phosphat-dehydrogenase
(GAPDH) (fw ACATGGCCTCCAAGGAGTAAGA, 1040–1062 NM_001206359.1, rev GATCGAG
TTGGGGCTGTGACT, 1188–1168, probe HEX-CCACCAACCCCAGCAAGAG-BHQ1, 1114–1132) [22].
The TaqMan Universal PCR 2× Mastermix (Life Technologies, Carlsbad, CA, USA) and 100 ng of DNA
isolated from blood using the DNeasy blood and tissue kit (Qiagen) were used.
3. Results
3.1. Detection of Antibodies against PCMV in Pig and Human Sera
Using a recently developed Western blot assay based on two recombinant protein sequences
corresponding to the N-terminus and C-terminus of the glycoprotein B of PCMV [14], as well as
two newly produced PCMV tegument proteins, sera from different pig breeds were screened for
PCMV-specific antibodies (Figure 1). With exception of the U54A tegument protein, all recombinant
proteins were stable, as shown by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) (Figure 1a), and all were detected by an antiserum against the His-tag (Figure 1b).
When pig sera were screened, all four recombinant PCMV-derived proteins were detected by some pig
sera, among them were pigs confirmed to be PCMV-infected by PCR. Negative pig sera did not react
with the PCMV proteins. Surprisingly, also some human sera reacted with the PCMV proteins, for
example serum from individual 6331, whereas others (individual 9858) did not react (Figure 1b).
Altogether, 35 pig sera samples from three different pig breeds and 48 sera samples from humans
working as butchers, having close contact with pigs, or working in the meat industry as well as healthy
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blood donors were tested. Twenty-six pigs and four humans were found to be positive (Figure 2,
Table 1). Some of the human sera samples analyzed here were the same as those that previously tested
negative for PERV transmission [18].
 
Figure 1. Western blot analysis of human and pig sera using porcine cytomegalovirus (PCMV) proteins
as antigens. (a) SDS-PAGE and Coomassie blue staining of purified recombinant PCMV-derived
proteins: R1, N-terminal part of gB, R2, C-terminal part of gB, UA, tegument protein U54A, UB,
tegument protein U54B, M, marker proteins; (b) Western blot analysis using antibodies against the
His-tag, pig serum 2994, human sera 6331 and 9858. Antibodies were used at the following dilutions:
anti-His antibodies 1:1000, pig serum 2994 1:300, human sera 6331 and 9858 were used 1:300, anti-mouse
serum 1:1000, anti-human serum 1:1000, and anti-pig serum 1:1000.
 
Figure 2. Western blot analysis of sera from humans working as butchers or in the meat industry using
the R1 and R2 recombinant protein of glycoprotein B (gB) of PCMV. Anti-His serum was used as a
positive control (lane 2). Anti-His serum was used at a dilution of 1:1000, human sera at 1:300, and
anti-human serum at 1:1000. Lane 1, marker proteins, lane 2, antibodies against the His tag, lane 4 to
14, different human sera samples.
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Table 1. Testing of pig and human sera for PCMV by Western blot analysis, in parallel PCMV infection
was determined by PCR. n.t., not tested.
Number Tested PCR Western Blot Analysis Using PCMV Proteins
R1 R2 UA UB
Human sera
Butcher and workers in the meat production industry 24 n.t. 1 3 n.t. n.t.
Blood donors 24 n.t. 1 0 n.t. n.t.
Pig sera
Aachen minipigs 12 2 3 12 6 6
Göttingen minipigs 11 5 2 4 4 9
Slaughterhouse pigs 12 2 4 10 12 9
3.2. Sequence Comparison of PCMV and Other Herpesviruses
The presence of antibodies in human sera suggests that either the human individuals are infected
with PCMV or the antibodies are cross-reacting with a human herpesvirus. The seroprevalance of
human herpesviruses is relatively broad worldwide. Specifically, HSV-1 50–90%, HSV-2 4–60%, VZV
5–80%, CMV 52–99%, HHV-6 39–100%, HHV-7 96%, EBV 66–85%, and KSHV 1–60% of the population
are seropositive [23,24]. In individuals infected with the human immunodeficiency virus HIV-1, more
and multiple herpesviruses have been described. EBV, HHV-8, CMV, and HSV-1 were detected in 90%,
57%, 31%, and 16% of samples compared with 48%, 24%, 2%, and 2% of samples from controls [24].
Phylogenetic studies showed that PCMV belongs to the genus Roseolovirus, and that it is closely related
to HHV-6 and HHV-7 [25]. Since VZV, EBV, and HCMV are not so closely related, an alignment of
the sequences of the gB protein used for our Western blot analysis was only possible for HHV-6 and
HHV-7 (Figure 3).
 
Figure 3. Multiple alignment of protein sequences of gB of PCMV, HHV-6A, HHV-6B, and HHV-7. gB
N-terminus, N-terminal part of gB of PCMV corresponding to R1, gB C-terminus, C-terminal part of
gB of PCMV, corresponding to R2. The accession numbers are indicated. Dots represent missing amino
acids and deletions. Arrows indicate related amino acids between PCMV and HHV-6A (black arrows,
identical amino acids; red arrows, conserved amino acids, R=K, L=I=V, F=Y).
3.3. Human Antibodies against PCMV and HCMV
Although HCMV is not closely related to PCMV—it has only a similar name—we nevertheless
analyzed whether antibodies in human sera specific for PCMV are the result of an infection of humans
with this porcine virus, or whether there may be a cross-reactivity with HCMV. For this, human sera
reacting positive or negative against PCMV were tested for antibodies against HCMV. No correlation
between the reactivity against PCMV and HCMV was found (Table 2), clearly indicating that there is
no cross-reactivity between sera against both viruses.
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Table 2. Testing human sera for porcine cytomegalovirus (PCMV) and human cytomegalovirus
(HCMV) by Western blot analysis.
Serum Number Western Blot Analysis PCMV (1) Result HCMV (2)
R1 R2
1 (3) − +/− >250
2 (3) − + >250
3 − + -
4 − +/− -
5 − + -
6 − − >250
7 − − 6.1
8 − − >250
9 − − 214.1
10 − − 180.7
(1) Serum dilution 1:5/1:10, two recombinant parts of the glycoprotein gB of PCMV, R1 and R2, were used as
antigens; (2) Performed at Labor Berlin, chemiluminescent microparticle immunoassay (CMIA), units; (3) Gray:
Identical results.
Only in two cases (20%) were identical results found in the testing for both viruses; in 80% no
correlation was observed.
Most interestingly, when a preparation of Cytotect was tested in the Western blot analysis with the
recombinant proteins R1 and R2, a strong reaction was observed (Figure 4a). Cytotect is a commercial
anti-HCMV polyclonal immunoglobulin preparation from human plasma from HCMV-positive
individuals used for the treatment of HCMV infections in various clinical settings [26], as well as to
prevent HCMV transmission to the fetus during pregnancy [27]. Titers of 1:200 in the case of protein
R1 as an antigen and 1:400 in the case of protein R2 were observed (Figure 4a). Cytotect also reacted











Figure 4. (a) Strong reaction of a Cytotect preparation against the recombinant gB proteins R1 and R2 of
PCMV. 1, marker, 2, anti-His-tag antibody 1:1000, anti-mouse antibodies 1:1000 as positive controls, 3–9,
dilution of the Cytotect preparation starting with 1:50, anti-human antibodies 1:1000; (b) left, reaction
of the Cytotect preparation (1:50) with the gB proteins R1 and R2, and two tegument proteins of PCMV,
UA, and UB; right, negative control, secondary human antibody 1:1000 only.
However, when 15 sera from humans with a well characterized status of HCMV immunoglobulin
were analysed in an Western blot assay using R1 and R2 of PCMV as antigens, no correlation was
observed (Table 3). Only in 4 cases (26%) identical results were obtained when testing for both viruses,
in 74% no correlation was observed.
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Table 3. Testing human sera for PCMV and HCMV by Western blot analysis.
Number Serum Number HCMV IgG (1) Western Blot Analysis Using PCMV gB Antigens (2)
R1 R2
1 914,640 − − +
2 (3) 914,644 − − −
3 (3) 914,672 + − +
4 914,714 − − +
5 914,814 + − −
6 914,854 − +
7 914,855 + − −
8 914,887 − − +
9 914,978 + − −
10 914,984 + − −
11 (3) 914,986 + − +
12 914,998 + − −
13 915,159 + − −
14 (3) 915,164 + − +
15 915,274 + − −
(1) Using the LIAISON CMV IgG II assay; (2) All sera were diluted 1:150; (3) Gray: identical result in PCMV (R2) and
HCMV testing.
3.4. Pig Sera Reacting with PCMV Reacted with HHV-6
Since there was no correlation between the reactivity against PCMV and HCMV (HHV-5),
confirming that PCMV and HCMV were not closely related and knowing that PCMV is closer related
to HHV-6 and HHV-7 [3], sera from pigs reacting against PCMV were screened for a reactivity against
HHV-6 using an immunofluorescence assay. Five pig sera positive for PCMV reacted positive in the
immunofluorescence assay for HHV-6, five pig sera negative for PCMV reacted negative (Figure 5
shows four of them). These data show that pig sera positively reacting against recombinant PCMV
proteins in an Western blot analysis also reacted positively in an immunofluorescence assay against

















Figure 5. Results of the immunofluorescence analysis of pig and human sera for antibodies reacting
against HHV-6. HHV-6 infected cells were used as antigen. In the upper row the reactivity of four
pig sera is shown, two of them were PCMV-negative two were PCMV-positive. The “positive control”
and the “negative control” are human sera with a known seroreactivity. In the upper row four human
sera were analyzed which in parallel were tested on a Western blot analysis using four recombinant
proteins of PCMV (Table 5). The bar corresponds to 50 µm.
3.5. Human Sera Reacting with HHV-6 Reacted with PCMVand Vice Versa
Furthermore, when sera from humans reacting positively or negatively against HHV-6 were
tested for reactivity against PCMV, a good correlation was observed (Table 4). Two sera samples
negative for HHV-6 were negative for PCMV, and out of four sera samples positive for HHV-6, only
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one did not react against PCMV, a serum with a low titer (1:32) against HHV-6. The human serum 6331
with the highest titer against HHV-6 reacted strongly against PCMV (Figure 1b, Table 4). On the other
hand, all human sera reacting positively in a Western blot analysis with recombinant PCMV proteins
also reacted positively in an immunofluorescence assay for HHV-6, with one exception—serum G2
(Table 5). The fact that all sera samples that were negative for PCMV also reacted with HHV-6 is not
surprising, given the high prevalence of HHV-6 in the human population.
Table 4. Correlation between the reactivity against porcine cytomegalovirus (PCMV) and human
herpesvirus-6 (HHV-6).
Number Serum Number HHV-6 (1) PCMV Western Blot Analysis
R1 R2 U54A U54B
1 11,415 − − − − −
2 10,301 − − − − −
3 9858 32 − − − −
4 7186 >64 − + − −
5 6515 32 − + − −
6 6331 >64 − + + +
(1) Immunofluorescence testing.
Table 5. Testing human sera for PCMV and HHV-6 by Western blot analysis and immunofluorescence assay.
Number Serum Number HHV-6 (1) PCMV Western Blot Analysis
R1 R2 U54A U54B
PCMV-positive sera
1 G2 − − + − +
2 G13 >64 − + − +
3 G15 16 − + + −
4 G23 >>64 +/− + + +
5 G24 16 − + − −
PCMV-negative sera
1 G16 >64 − − − −
2 G17 >64 − − − −
3 G18 >64 − − − −
4 G19 >>64 − − − −
5 G20 − − − − +
(1) Immunofluorescence testing.
4. Discussion
Porcine cytomegalovirus is one of the pathogens that should be eliminated from pigs intended
for use as organ donors in xenotransplantation. For this purpose, reliable diagnostic test systems
are needed, and recently sensitive PCR-based [28–32] as well as serological assays [14,33] have
been developed.
The positive Western blot result when testing human sera with recombinant PCMV proteins was
an interesting finding, which allowed to us speculate that PCMV may be able to infect humans. One
porcine virus that frequently infects humans is the hepatitis E virus (HEV), genotype 3 (gt3) (for review
see [34]). In most cases, this infection is asymptomatic and in certain regions in France up to 56% of
the population have antibodies against HEV, indicating a previous infection due to the consumption of
undercooked liver sausages called figatellu [35,36]. HEV is also transmitted to humans by contact with
pigs [34], and from human to human by organ transplants or blood donations [34]. Severe hepatitis
was observed mostly in patients with underlying liver disease and in immunosuppressed individuals
where HEV can cause a chronic or even fatal disease [34].
When analyzing the reason for the presence of reactive antibodies against PCMV in human sera, a
cross-reactivity with antibodies against HCMV and other herpesviruses, with the exception of HHV-6
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and HHV-7, can be excluded due to a lack of sequence homology [29]. In the case of HCMV, this was
confirmed experimentally by testing sera positive for antibodies against PCMV and HCMV in different
assays (Tables 2 and 3). In contrast, a cross-reactivity with HHV-6 was shown, since pig sera reacting
against PCMV also reacted with human cells infected with HHV-6, and human sera reacting with
HHV-6 recognized recombinant PCMV proteins (Figure 5, Tables 4 and 5). The fact that Cytotect, an
immunoglobulin preparation from HCMV-positive individuals, reacted with the PCMV proteins can
certainly be explained by the presence of antibodies against HHV-6 in the preparation. HHV-6A and
HHV-6B infect nearly the entire human population that has been tested. While HHV-6B is present in
almost 100% of the world’s population, HHV-6A appears to be less frequent in Japan, North America,
and Europe [37].
It is well known that HHV-6 and HHV-7 are close relatives of PCMV [3]. In a comparison of PCMV
gB with the corresponding region of other herpesviruses, the highest identities were found with human
herpesviruses 6 and 7 (HHV-6 and -7; 43.4% and 42.6%, respectively) [25]. Also in phylogenetic analysis,
the PCMV gB clustered with HHV-6 and HHV-7. Despite a considerable intra-species variation
(between the complete gB sequences of five different PCMV strains and isolates from the United
Kingdom, Germany, Spain, Japan, and Sweden, differences of 3.4% were found), similar sequences
exist in the gB of PCMV and HHV-6 (Figure 3), which could allow the binding of cross-reacting
antibodies. Regions of up to seven identical or conserved amino acids were detected (Figure 4), which
exceeds the size of common epitopes of approximately five amino acids [38]. Since PCMV is also
closely related to HHV-7, and a high homology in the sequence of the antigens used in Western blot
analyses was found (Figure 3), we cannot exclude a cross-reactivity with HHV-7. Unfortunately,
reliable detection methods for HHV-7 are not available and at hand, and in an immunofluorescence
assay on the basis of HHV-7-infected cells, no specific reaction could be observed due to a high
unspecific background.
HHV-6B is known to be associated with the childhood disease roseola infantum, and a spectrum
of other clinical diseases ranging from asymptomatic infection to acute febrile illnesses with severe
neurological complications [39]. Furthermore, HHV-6A and HHV-6B are associated with diverse
complications in transplant patients [40]. Most interestingly, both viruses can integrate their viral
sequences into the host cell genome [39]. Although it is unlikely that PCMV can infect human cells and
replicate in humans, it is unclear whether PCMV can induce similar diseases as HHV-6 and/or reduce
the survival time of the pig transplant. Nevertheless, elimination programs have been developed to
eliminate PCMV from pig breeds generated for xenotransplantation. They are based first of all on early
weaning, but may include Cesarean delivery or embryo transfer [4,41]. Unfortunately, there are still
no effective vaccines to prevent infection [42] or treatments to eliminate PCMV [43]. Antiviral drug
efficiently inhibiting HCMV in humans were ineffective against PCMV [44].
Herpesviruses are considered to specifically infect their own species [1,8]. However, the question
of whether PCMV can infect human cells and replicate in humans is still unanswered. There is one
publication reporting the infection of human fibroblasts [9], while co-cultivation of PCMV-infected pig
macrophages with two human cell lines (293 and Raji) did not facilitate virus transmission [10]. Our
own experiments also showed that human cells cannot be infected by PCMV [45]. Five human cell
lines (HeLa, 293T, TZM-bl, Jurkat, and HepG2) were spinoculated and incubated with serum from
one PCMV-infected animal. No PCMV was detected in the treated cells or in the pelleted supernatant
using a highly sensitive PCR [42].
This is the first report demonstrating an antibody cross-reactivity between PCMV and HHV-6.
However, this cross-reactivity is not unexpected, considering the sequence homology (Figure 3). In
this context, it may be interesting to discuss the question of whether the presence of antibodies against
HHV-6 may prevent infection with PCMV.
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